# Alnylam Pharmaceuticals, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Alnylam Pharmaceuticals, Inc).

## Overview

Alnylam Pharmaceuticals, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA interference (RNAi) medicines that silence disease-causing genes. It commercializes multiple approved therapies for rare diseases and transthyretin (ATTR) amyloidosis, while also generating revenue from collaborations and royalties where partners commercialize certain assets. The company has built internal marketing, market access, and distribution capabilities across the U.S., Europe, and Japan, and uses partners and distributors in other markets. Its business model combines direct product sales with partnered programs (e.g., royalties on partner-sold products) and continued investment in a broad clinical pipeline enabled by its RNAi platform and intellectual property estate.

## Products & services

• AMVUTTRA (vutrisiran) for ATTR amyloidosis (TTR franchise)
• ONPATTRO (patisiran) for hereditary ATTR polyneuropathy
• GIVLAARI (givosiran) for acute hepatic porphyria
• OXLUMO (lumasiran) for primary hyperoxaluria type 1
• Collaboration/partner programs (e.g., Roche, Regeneron, Sanofi)
• Royalty streams (e.g., Leqvio; Qfitlia via collaborators)

- **TTR franchise (ATTR amyloidosis)** (55%) — RNAi therapeutics AMVUTTRA and ONPATTRO sold for ATTR amyloidosis indications.
- **Global Rare franchise** (20%) — RNAi therapeutics GIVLAARI and OXLUMO for rare genetic/metabolic diseases.
- **Collaboration revenue** (20%) — Upfronts, milestones, and other revenue from partnered R&D/commercial agreements.
- **Royalties** (5%) — Royalties on partner commercial sales (e.g., Leqvio and Qfitlia) and similar streams.

- AMVUTTRA (vutrisiran) for ATTR amyloidosis (TTR franchise)
- ONPATTRO (patisiran) for hereditary ATTR polyneuropathy
- GIVLAARI (givosiran) for acute hepatic porphyria
- OXLUMO (lumasiran) for primary hyperoxaluria type 1
- Collaboration/partner programs (e.g., Roche, Regeneron, Sanofi)
- Royalty streams (e.g., Leqvio; Qfitlia via collaborators)

## Customers

For its directly commercialized medicines (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), Alnylam’s immediate customers are specialty distributors and healthcare providers, with demand driven by specialist physicians treating rare diseases and ATTR amyloidosis. Patient access is heavily influenced by third-party payors, so payer coverage, reimbursement pathways, and health-system adoption are central to commercialization. In addition to product sales, Alnylam earns revenue from pharmaceutical partners through collaboration arrangements and royalties where collaborators hold commercialization rights (e.g., Leqvio and Qfitlia). The company’s commercial execution depends on educating prescribers, supporting patients, and navigating country-by-country regulatory and market access requirements.

- **ATTR amyloidosis prescribers and centers (cardiology/neurology)** (primary) — Adopt AMVUTTRA/ONPATTRO based on clinical profile, site readiness, and patient demand; requires health-system engagement and education.
- **Rare disease specialists (metabolic/hepatology/genetics)** (secondary) — Prescribe GIVLAARI and OXLUMO for small, identifiable patient populations; access depends on payer approval and specialty distribution.
- **Third-party payors (public and private)** (primary) — Determine formulary placement and reimbursement pathways that enable or restrict patient access for high-cost rare disease therapies.
- **Pharmaceutical collaborators/licensees** (secondary) — Commercialize partnered assets and pay Alnylam collaboration revenue and/or royalties (e.g., Leqvio; Qfitlia; partnered pipeline programs).

- Specialist physicians and treatment centers prescribing RNAi therapies
- Hospitals/health systems needing set-up for ATTR-CM patient pathways
- Third-party payors controlling coverage and reimbursement decisions
- Specialty pharmacies/distributors purchasing and dispensing high-cost drugs
- Pharma collaborators paying milestones/cost share under partnerships
- Patients/caregivers influenced by support programs and access logistics

## Geography

Alnylam operates as a global commercial-stage company with internal commercial infrastructure established across the U.S., Europe, and Japan, and ongoing expansion into additional markets. For AMVUTTRA’s ATTR-CM launch, the company highlights U.S. commercialization and launches in Japan and Germany, with further markets in regulatory review and launch preparation. Net product revenues are discussed by region (United States, Europe, and Rest of World) in quarterly reporting, reflecting meaningful exposure to ex-U.S. reimbursement and launch timing. The company also uses strategic partners, distributors, or contract sales forces in many territories, which can accelerate reach but adds dependency on third parties and local compliance execution.

- Core commercial build-out across the U.S., Europe, and Japan
- AMVUTTRA ATTR-CM launched in the U.S., Japan, and Germany
- Regional product revenue reporting: United States, Europe, Rest of World
- Partner/distributor model used in many territories outside key markets
- Global footprint increases exposure to local pricing and reimbursement rules
- Regulatory sequencing by country drives launch timing and revenue mix

## Strategy

Alnylam’s strategy centers on expanding its RNAi therapeutic platform into a multi-product global business by scaling commercial operations and sequentially launching products across geographies. In ATTR amyloidosis, it is leveraging experience from hereditary ATTR polyneuropathy to drive broader adoption (including cardiomyopathy) through health-system set-up, payer access work, and physician/patient education. The company continues to invest heavily in R&D and late-stage capabilities, while using collaborations with large pharma (e.g., Roche, Regeneron, Sanofi, Novartis/MDCO) to fund development and extend commercialization reach. Management has also articulated a goal of financial self-sustainability, while continuing to expand manufacturing capacity and global compliance capabilities to support growth.

- **Expand ATTR franchise penetration (including ATTR-CM)** (short-term) — AMVUTTRA growth is a key driver of revenue and operating leverage; adoption depends on sites, payors, and prescriber behavior.
- **Scale global commercial and market access capabilities** (medium-term) — Direct commercialization in major markets requires sustained investment in sales, market access, distribution, and patient support.
- **Advance RNAi platform and pipeline while leveraging collaborations** (long-term) — Pipeline productivity and partnered economics underpin long-term growth and diversify beyond current products.

- Scale global commercial operations for sequential multi-country launches
- Drive ATTR-CM adoption via health-system set-up, access, and education
- Invest in RNAi pipeline using GalNAc/LNP and newer conjugate approaches
- Use collaborations to share risk, fund R&D, and monetize select assets
- Expand manufacturing and production capacity to support demand
- Strengthen compliance programs to support promotion across jurisdictions

## Risks

Alnylam’s near- to medium-term performance is sensitive to sustaining and growing AMVUTTRA sales, including successful execution of launches and payer access in ATTR-CM. Like most biopharma companies, it faces high clinical development and regulatory risk across its pipeline, where delays or failures can materially reduce future product options. The company relies on third parties for manufacturing and clinical trials and, in some geographies, for commercialization—creating operational and quality/compliance dependencies outside its direct control. Additional risks include pricing and reimbursement pressure in the U.S. and internationally, competitive therapies (including other RNAi and non-RNAi approaches), and technology/cybersecurity risks amplified by increased cloud usage.

- **Inability to sustain and grow AMVUTTRA revenues** [high] — Management identifies AMVUTTRA sales growth as critical; weaker demand or access could materially harm results and valuation.
- **Commercialization may be less successful than anticipated** [high] — Adoption depends on regulatory terms, physician acceptance, and reimbursement; shortfalls reduce realized market opportunity.
- **Clinical development delays or failures** [high] — High failure rates and long timelines can prevent approvals and impair the ability to commercialize future products.
- **Third-party dependence (manufacturing, trials, partners, cloud providers)** [medium] — Failures by CMOs/CROs/partners or cyber incidents at service providers can disrupt supply, delay development, or compromise data.

- Concentration risk if AMVUTTRA growth slows or adoption underperforms
- Launch execution risk: payer coverage and health-system readiness
- Clinical/regulatory failure risk across pipeline programs
- Third-party manufacturing and clinical trial execution dependencies
- Partner performance risk for collaborator-commercialized assets
- Pricing/reimbursement pressure and policy changes affecting promotion
- Competition from other RNAi and alternative modality programs
- Cybersecurity and cloud service provider failures disrupting operations

## Accounting

Alnylam’s net product revenue is recognized when the customer obtains control of the product, and reported net of variable consideration such as allowances and accruals. Reported revenue depends materially on management estimates for reserves tied to contractual terms and expected sell-through of inventory in distribution channels, which are updated quarterly and can create period-to-period adjustments. The company also has meaningful non-product revenue streams (collaboration revenue and royalties), which can be volatile based on partner activity, contract terms, and timing of milestones or other performance-based components. Investors should also monitor judgments around contingent liabilities and commitments (including operating leases) and the accounting for collaboration arrangements, which can affect comparability across quarters.

- **Net product revenue reserves and variable consideration** — Impacts reported net product revenues and gross-to-net adjustments

- Net product revenue recognized at control transfer; net of allowances
- Quarterly updates to reserves for channel inventory and variable consideration
- Collaboration revenue and royalties can be timing- and contract-driven
- Partner arrangements require judgment on classification and recognition
- Operating lease commitments affect expense recognition and disclosures
- Quarter-to-quarter revenue mix shifts can reduce comparability

---

*Last updated: 2026-09-24T12:08:19.071383+00:00*